Karyopharm Financial Statements From 2010 to 2024

KPTI Stock  USD 1.39  0.09  6.08%   
Karyopharm Therapeutics financial statements provide useful quarterly and yearly information to potential Karyopharm Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Karyopharm Therapeutics financial statements helps investors assess Karyopharm Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Karyopharm Therapeutics' valuation are summarized below:
Gross Profit
151.9 M
Profit Margin
(0.98)
Market Capitalization
170.3 M
Enterprise Value Revenue
1.0672
Revenue
146 M
We have found one hundred twenty available fundamental ratios for Karyopharm Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Karyopharm Therapeutics last-minute fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year.
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Operating Cycle of 268. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
This module can also supplement Karyopharm Therapeutics' financial leverage analysis and stock options assessment as well as various Karyopharm Therapeutics Technical models . Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets238.3 M240.4 M204.1 M
Slightly volatile
Total Current Liabilities73 M69.5 M31.9 M
Slightly volatile
Property Plant And Equipment NetM4.9 M2.6 M
Slightly volatile
Current Deferred Revenue83.5 M79.5 M26.8 M
Slightly volatile
Accounts Payable3.5 M3.1 M3.1 M
Pretty Stable
Cash101.7 M52.9 M87.3 M
Slightly volatile
Non Current Assets Total6.2 M6.5 M18.3 M
Slightly volatile
Other Assets0.951.05.6 M
Slightly volatile
Cash And Short Term Investments201.8 M192.1 M172.9 M
Slightly volatile
Common Stock Shares Outstanding119.9 M114.2 M49.5 M
Slightly volatile
Liabilities And Stockholders Equity238.3 M240.4 M204.1 M
Slightly volatile
Non Current Liabilities Total322.5 M307.2 M138.5 M
Slightly volatile
Other Current Assets12.4 M11.8 M4.4 M
Slightly volatile
Other Stockholder Equity748.9 M1.4 B640 M
Slightly volatile
Total Liabilities395.5 M376.6 M158 M
Slightly volatile
Property Plant And Equipment Gross12 M11.4 M4.5 M
Slightly volatile
Total Current Assets215.6 M233.9 M184.7 M
Slightly volatile
Short Term Debt5.5 M3.3 M9.4 M
Very volatile
Property Plant Equipment2.2 M1.3 M1.9 M
Slightly volatile
Common Stock Total Equity14.5 K13.8 K6.4 K
Slightly volatile
Capital Surpluse824.8 M1.5 B700.2 M
Slightly volatile
Common Stock7.1 K13.8 K5.9 K
Slightly volatile
Other Liabilities260.4 M248 M78.7 M
Slightly volatile
Net Invested Capital33 M34.7 M137.1 M
Pretty Stable
Net Working Capital233.5 M164.4 M160.8 M
Slightly volatile
Short and Long Term Debt Total155.8 M177 M121.8 M
Slightly volatile
Long Term Debt Total121.2 M135.6 M109.6 M
Slightly volatile
Capital Stock9.5 K13.8 K7.4 K
Slightly volatile
Net Receivables25.8 M27 M14.3 M
Slightly volatile
Capital Lease Obligations8.7 M6.1 M13.1 M
Slightly volatile
Non Current Liabilities Other929.1 K978 K73.9 M
Slightly volatile

Karyopharm Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization503.5 K530 K1.3 M
Slightly volatile
Selling General Administrative67.5 M131.9 M57.8 M
Slightly volatile
Total Revenue153.3 M146 M56.6 M
Slightly volatile
Gross Profit147.6 M140.6 M54.9 M
Slightly volatile
Other Operating Expenses177.9 M275.6 M152.8 M
Slightly volatile
Research Development108.8 M138.2 M93.5 M
Slightly volatile
Cost Of Revenue5.2 M5.5 M41.7 M
Pretty Stable
Total Operating Expenses176.3 M270.1 M151.4 M
Slightly volatile
Non Operating Income Net Other2.1 M2.6 M1.6 M
Slightly volatile
Interest Income10.2 M9.8 M2.9 M
Slightly volatile
Tax Provision203.5 K266 K167.8 K
Slightly volatile
Reconciled Depreciation613.7 K566 K731.6 K
Very volatile

Karyopharm Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.8 M21.7 M16.1 M
Slightly volatile
Begin Period Cash Flow98.7 M136.3 M84.6 M
Slightly volatile
Other Cashflows From Financing Activities7.5 M7.9 M34 M
Pretty Stable
Depreciation622.5 K530 K537.5 K
Slightly volatile
Total Cash From Financing Activities1.1 M1.1 M95.6 M
Pretty Stable
End Period Cash Flow102.9 M52.9 M88.4 M
Slightly volatile
Sale Purchase Of Stock3.4 M3.6 M40.1 M
Slightly volatile
Change To Netincome22.7 M40.4 M18.7 M
Slightly volatile
Net Borrowings133.5 M150.2 M163.5 M
Slightly volatile
Issuance Of Capital Stock129.8 M154.7 M133.6 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.640.6766682
Pretty Stable
Operating Cycle268270203
Slightly volatile
Days Of Payables Outstanding291208197
Slightly volatile
Inventory Turnover2.611.79825.1374
Slightly volatile
Ebt Per Ebit0.851.10221.035
Slightly volatile
Payables Turnover1.941.75222.1826
Slightly volatile
Long Term Debt To Capitalization5.174.92381.1808
Slightly volatile
Cash Per Share1.61.68195.347
Slightly volatile
Quick Ratio3.03.15367.2679
Pretty Stable
Dividend Paid And Capex Coverage Ratio1.2 K1.1 K594
Slightly volatile
Net Income Per E B T0.81.00230.9879
Slightly volatile
Cash Ratio0.720.761325.4132
Pretty Stable
Days Of Inventory Outstanding216203136
Slightly volatile
Days Of Sales Outstanding52.7467.389867.5947
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.151.034
Slightly volatile
Current Ratio3.23.366873.5905
Pretty Stable
Fixed Asset Turnover15.6229.912518.0011
Slightly volatile
Capital Expenditure Coverage Ratio1.2 K1.1 K594
Slightly volatile
Debt Ratio0.760.72460.3312
Slightly volatile
Price Sales Ratio0.640.6766682
Pretty Stable
Receivables Turnover6.965.41635.6962
Slightly volatile
Asset Turnover0.640.60740.2324
Slightly volatile
Gross Profit Margin0.780.96250.9386
Pretty Stable

Karyopharm Fundamental Market Drivers

Cash And Short Term Investments192.1 M

Karyopharm Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Karyopharm Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Karyopharm Therapeutics income statement, its balance sheet, and the statement of cash flows. Karyopharm Therapeutics investors use historical funamental indicators, such as Karyopharm Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karyopharm Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karyopharm Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue79.5 M83.5 M
Total Revenue146 M153.3 M
Cost Of Revenue5.5 M5.2 M
Ebit Per Revenue(0.89)(0.93)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.25)
Revenue Per Share
1.279
Quarterly Revenue Growth
0.005
Return On Assets
(0.27)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.